Thioredoxin Systems — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Thioredoxin Systems is a preclinical-stage biotech company tackling the global crisis of antimicrobial resistance through a novel mechanism of action. Its lead candidate, EbsArgent™, is a combination of ebselen and silver ions designed to disable the essential bacterial thioredoxin reductase system, showing efficacy against all WHO-classified critical priority pathogens. The company is initially focused on developing EbsArgent for complicated urinary tract infections, a significant unmet medical need with high hospitalization rates. Founded on the groundbreaking redox research of Professor Arne Holmgren, the company is privately held and advancing its program through preclinical development.

Infectious Disease

Technology Platform

Targeted inhibition of the bacterial thioredoxin reductase system using a synergistic combination of ebselen and silver ions (EbsArgent™), a novel mechanism of action designed to overcome antimicrobial resistance.

Opportunities

The global AMR crisis creates an urgent, large, and growing unmet medical need, supported by new regulatory incentives and potential premium pricing for novel antibiotics.

The EbsArgent™ platform shows broad-spectrum efficacy against critical priority pathogens and may be difficult for bacteria to resist, offering a potential best-in-class profile.

Success in cUTI could pave the way for expansion into other serious bacterial infections.

Risk Factors

High risk of failure inherent in drug development, as preclinical results may not translate to human safety and efficacy.

The antibiotic market suffers from commercial challenges due to stewardship requirements limiting use.

The company is pre-revenue and will require significant capital to advance through costly clinical trials, facing intense competition for funding.

Competitive Landscape

The competitive landscape includes large pharma with legacy antibiotic portfolios and a small number of biotechs developing novel-mechanism antibiotics (e.g., targeting novel enzymes, lysins, or virulence factors). EbsArgent's unique thioredoxin system target differentiates it from most current clinical-stage candidates. However, it will compete for market share with recently approved drugs for MDR infections and any new entrants that reach the market concurrently.

More companies in Sweden →